Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504) against established murine adenocarcinomas (MAC)

2,3,5-Trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-5504), an inhibitor of 5-lipoxygenase and thromboxane A(2) synthase and a scavenger of active oxygen species, has been shown to exhibit profound antitumour activity against three established murine adenocarcinomas (MACs) that are generally refractory to standard cytotoxic agents. For the cachexia-inducing MAC16 tumour, optimal anti-tumour activity was seen at dose levels of 10 and 25 mg kg(-1) day(-1), together with a reversal of cachexia and a doubling of the time to sacrifice of the animals through cachexia from 8 days to 17 days. The remaining tumour fragments showed extensive necrosis in regions distal from the blood supply. Growth of the MAC13 tumour was also effectively suppressed at dose levels between 5 and 50 mg kg(-1) day(-1), resulting in a specific growth delay between 1.0 and 1.2. Growth of the MAC26 tumour was also inhibited in a concentration-related manner. with doses of 25-50 mg kg(-1) day(-1) being optimal. Anti-tumour activity towards all three tumours at low dose levels of CV-6504 was effectively suppressed by concurrent administration of linoleic acid (1 g kg(-1) day(-1)), suggesting that inhibition of linoleate metabolism was responsible for the anti-tumour effect. Tumour sensitivity may be correlated with increased DT-diaphorase levels that are required to metabolise CV-6504 to the active hydroquinone, which inhibits 5-lipoxygenase activity.